Supernus Pharm (SUPN) Stock Price, Quote & News

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the mon...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 838 2500

Website: www.supernus.com

Address:

9715 Key West Avenue, Rockville, United States

CynthiaOreily777 Aug. 3 at 2:20 PM

$BRK.B $CVX $SUPN $OXY $FSLR Berkshire Hathaway Class B offers diversified exposure, Chevron benefits from disciplined energy production, Supernus advances neurological therapies, Occidental generates strong free cash flow, and First Solar leads U.S. solar manufacturing.

0 · Reply

EarningsInsider Aug. 3 at 1:45 PM

https://www.marketbeat.com/earnings/reports/2026-8-3-supernus-pharmaceuticals-inc-stock/ $SUPN Supernus Pharmaceuticals Earnings Transcrip

0 · Reply

DonCorleone77 Aug. 3 at 1:17 PM

$ATKR $FERG $SUPN $INDV $BMY PRE-MARKET MOVERS: Currently Higher: - Atkore (ATKR) up 27.9% after entering into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8B - Ferguson (FERG) up 8.2% ahead of its entry into the S&P 500 - Supernus (SUPN) up 14.3% after the company and Indivior entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Indivior (INDV) up 1.2% after Supernus and the company entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Bristol Myers (BMY) up 3.1% after Financial Times reported AstraZeneca (AZN) is in discussions to combine with the company in a deal valued at nearly $400B Currently Lower After Earnings: - Sportradar (SRAD) down 19.2% - Krystal Biotech (KRYS) down 5.6% - TG Therapeutics (TGTX) down 2.7% - Marriott (MAR) down 2.2% Currently Also Lower: - AstraZeneca (AZN) down 7.1% after Financial Times reported the company is in discussions to combine with Bristol Myers Squibb in a deal valued at nearly $400B - Circle Internet (CRCL) down 5.6% after Morgan Stanley downgraded the stock to Underweight with a price target of $38, down from $106

0 · Reply

briefingcom Aug. 3 at 12:30 PM

$SUPN: Supernus Pharma (+14.3%) and Indivior Pharmaceuticals $INDV to merge; expected to close in Q4 of 2026.

0 · Reply

OpenOutcrier Aug. 3 at 12:23 PM

$SUPN (+13.2% pre) Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal https://ooc.bz/l/109615

0 · Reply

Estimize Aug. 3 at 12:06 PM

$SUPN reported 0.53 EPS and 219.06 revenue for Q2. http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_content=SUPN&utm

0 · Reply

notreload_ai Aug. 3 at 12:00 PM

$SUPN and $INDV merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility. https://notreload.xyz/xy/supn-indv-merge-to-form-2-2b-cns-leader/

0 · Reply

topstockalerts Aug. 3 at 11:55 AM

Pre Market Top Gainers PT2 $SXTC $ZBAO $ATKR $SUPN $CABR

0 · Reply

topstockalerts Aug. 3 at 11:16 AM

Pre Market Top Gainers PT2 $SXTC $ZBAO $ATKR $SUPN $CABR

0 · Reply

RTPRwire Aug. 3 at 11:09 AM

$SUPN climbed +25% on M&A / acquisition following a Globe Newswire release. Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock transaction creating a diversified CNS biopharmaceutical company with $2.2B in combined revenues and $125M in expected annual cost syn RTPR pushed this release out to users at 6:30:00 AM ET

0 · Reply